Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04990440
Other study ID # CR109057
Secondary ID 2020-005900-2177
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 2, 2021
Est. completion date March 9, 2022

Study information

Verified date April 2023
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo, in participants with moderate-to-severe atopic dermatitis (AD).


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date March 9, 2022
Est. primary completion date March 9, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Have atopic dermatitis (AD) for at least 1 year (365 days) prior to the first administration of study intervention as determined by the investigator through participant interview and/or review of the medical history - Have a history of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable (example, due to important side effects or safety risks) - Have an Eczema Area and Severity Index (EASI) score greater than or equal to (>=) 16 at screening and at baseline - Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study - Must be willing to undergo 4 skin biopsies - Have an Investigator Global Assessment (IGA) score >=3 at screening and at baseline - Have an involved body surface area (BSA) >=10 percent (%) at screening and at baseline Exclusion Criteria: - Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances - Has ever received any Human interleukin-1 (IL-1) antagonist (example, including but not limited to anakinra, rilonacept)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bermekimab
Participants will receive bermekimab IV.
Placebo
Participants will receive placebo IV.

Locations

Country Name City State
Argentina Clínica Adventista Belgrano Caba
Argentina Conexa Investigacion Clinica S.A. Caba
Argentina STAT Research S.A. Caba
Argentina CARE - Centro de Alergia y Enfermedades Respiratorias Ciudad Autonoma de Buenos Aires
Argentina CINME - Centro de Investigaciones Metabolicas Ciudad de Buenos Aires
United States Clinical Research Institute of Michigan, LLC Chesterfield Michigan
United States Modern Research Associates Dallas Texas
United States Dawes Fretzin Clinical Research Group Indianapolis Indiana
United States Progressive Clinical Research San Antonio Texas
United States Texas Dermatology and Laser Specialists San Antonio Texas
United States Vital Prospects Clinical Research Institute, PC Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (Greater Than or Equal to [>=] 75 Percent [%] Improvement From Baseline) Percentage of participants with EASI-75 (>=75% improvement from Baseline in EASI score) was planned to be reported in this outcome measure. The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The total score is the sum of the four body-region scores ranged from 0.0 to 72.0, with higher scores reflecting greater disease severity. Week 16
Secondary Serum Concentrations of Bermekimab Over Time Serum concentrations of bermekimab was planned to be reported up to Week 20 but due to premature study termination, planned data collection and analysis could not be performed for this outcome measure. Up to Week 20
Secondary Number of Participants With Antibodies to Bermekimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs]) Number of participants with ADAs and NAbs to bermekimab was planned to be reported up to Week 16 but due to premature study termination, planned data collection and analysis could not be performed for this outcome measure. Up to Week 16
Secondary Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention up to end of study was considered as treatment-emergent. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. Any SAEs occurring at or after the initial administration of study intervention up to end of the study was considered as treatment-emergent. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With AEs Leading to Discontinuation of Study Intervention Percentage of participants with AEs leading to discontinuation of study intervention was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With AEs Reasonably Related to Study Intervention Percentage of participants with AEs reasonably related to study intervention was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With Adverse Events of Infusion-related Reactions Percentage of participants with adverse events of infusion-related reactions was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With AEs of Infections Percentage of participants with AEs of infections (including serious infections and infections requiring oral or parenteral antimicrobial treatment) was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With Clinically Significant Abnormalities in Vital Signs In this outcome measure, percentage of participants with clinically significant abnormalities in vital sign (respiratory rate) was reported. The clinical significance was determined by the investigator. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With Clinically Significant Abnormalities in Laboratory Tests In this outcome measure, percentage of participants with >=2 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade in laboratory parameter 'clinical chemistry-potassium (normal range: 3.5 to 5.2 mmol/L)' was reported. Grading was done as: Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening). The clinical significance was determined by the investigator. Due to premature study termination, data collected up to Week 6 were analyzed and reported for this outcome measure. Up to Week 6
Secondary Percentage of Participants With Both Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 and a Reduction From Baseline of >=2 Points Percentage of participants with both vIGA-AD score of 0 or 1 and a reduction from baseline of >=2 points was reported. IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale ranged from 0 to 4, where 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. Higher scores indicated greater severity. The IGA score was selected using the morphological descriptors that best described the overall appearance (erythema and population/infiltration) of the AD lesions at a given time point. Week 16
Secondary Percentage of Participants With Improvement (Reduction) of Eczema-related Itch Numeric Rating Scale (NRS) Score of >=4 From Baseline Among Participants With a Baseline Itch Value >=4 Percentage of participants with improvement (reduction) of eczema-related itch NRS score of >=4 from baseline among participants with a baseline itch value >=4 was reported in this outcome measure. The eczema skin pain and itch NRS was a 2-item (pain and itch) patient-reported outcome (PRO) developed by the sponsor that participants used to rate the severity of their eczema-related skin pain and itch daily. To rate the severity of eczema-related itch, participants were asked the following question: 'how would you rate your itch at the worst moment during the previous 24 hours' and the response was scored on a scale of 0 (no itch) to 10 (worst itch imaginable). Week 16
Secondary Percentage of Participants With EASI-90 Percentage of participants with EASI-90 was planned to be reported. The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The total score is the sum of the four body-region scores ranged from 0.0 to 72.0, with higher scores reflecting greater disease severity. Week 16
See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Terminated NCT04086121 - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 Phase 2
Recruiting NCT04011215 - Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2) N/A
Completed NCT04635072 - Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis Early Phase 1
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT01945086 - A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis Phase 2
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Completed NCT02900131 - Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients Phase 2
Completed NCT03568136 - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Phase 2
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT03672383 - Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation) N/A
Completed NCT03634345 - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. Phase 1
Enrolling by invitation NCT04761978 - Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Completed NCT03663673 - Effect of Different Skin Creams on TEWL Phase 1
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Completed NCT02637206 - Skin Irritation Study of GSK2894512 Cream Phase 1
Completed NCT05544591 - Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05094700 - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants N/A
Completed NCT02590289 - A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects Phase 1